Navigation Links
Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
Date:2/7/2011

nts included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to the potential regulatory approval and commercialization of fidaxomicin, future activities conducted under the collaboration and license agreement, the potential benefits of the collaboration and license agreement, Optimer's potential receipt of up-front, milestone and royalty payments, the incidence of CDI and limitations of current treatment options. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's and Astellas' respective businesses including, without limitation, risks relating to: the implementation and continuation of the collaboration and license agreement, each party's performance of its respective obligations under the collaboration and license agreement, Optimer's and Astellas' ability to commercialize fidaxomicin, the ability to maintain market exclusivity for fidaxomicin in the territory, Astellas' ability to terminate the collaboration and license agreement, the development of alternative treatments for or means of preventing CDI, whether and when regulatory authorities will review or approve Optimer's or Astellas' applications for marketing approval of fidaxomicin, whether healthcare professionals will prescribe fidaxomicin, if approved, whether fidaxomicin will receive reimbursement coverage from healthcare payors and government agencies, the timing and receipt of payments and fees, if any, from Astellas and other risks detailed in Optimer's filings with the Securities and Exchange Commission. ContactsOptimer Ph
'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... SAN DIEGO , May 4, 2015 /PRNewswire/ ... an oncology company focused on the clinical development ... pre-clinical data showing mitochondria-specific effects of the Company,s ... significantly enhanced anti-tumor activity when combined with a ... study found ME-344 to be a potent inhibitor ...
(Date:5/4/2015)... 4, 2015 The Pharmacy Workforce Center recently ... that pharmacy has shifted toward a female-dominated profession. With ... managers, there is an incredible opportunity for women to ... decade. In a new blog post ... Insights , Eden Sulzer, director of the Women ...
(Date:5/4/2015)... -- NeuroSigma ® , Inc. (NeuroSigma), a California ... study of its Thin Film Nitinol (TFN) flow diverter were ... at the 53 rd Annual Meeting of the American ... A copy of the study abstract can be accessed via ... Mayo Clinic was primarily funded through a Small Business Technology ...
Breaking Medicine Technology:MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5Cardinal Health Expert Discusses Latest Research On Gender Gap In Pharmacy 2Cardinal Health Expert Discusses Latest Research On Gender Gap In Pharmacy 3NeuroSigma's Thin Film Nitinol Flow Diverting Stent Results Presented at the American Society of Neuroradiology Meeting 2NeuroSigma's Thin Film Nitinol Flow Diverting Stent Results Presented at the American Society of Neuroradiology Meeting 3NeuroSigma's Thin Film Nitinol Flow Diverting Stent Results Presented at the American Society of Neuroradiology Meeting 4
(Date:5/4/2015)... San Diego Fertility Center (SDFC) ... brand new, 13,700 square foot facility scheduled to open ... not only provide fertility treatment and services for the ... and educational events to a number of local and ... door to their current Carmel Valley/Del Mar location and ...
(Date:5/4/2015)... May 04, 2015 Dr. Benjamin Stong ... proudly offers the latest non-surgical double-chin eliminator. Dr. ... plastic surgeon in Atlanta to offer Kybella treatments ... be injected specifically under the chin, promising to safely ... Before Kybella, patients who sought immediate solutions for their ...
(Date:5/4/2015)... May 04, 2015 Unlike some camps, the Nike ... knowledge. The goal is to educate first and train second, ... This ensures that the young runners are building the knowledge base ... few of the topics covered include Effort Based Training, Running Heroes, ... used to be? This is not a camp where kids ...
(Date:5/4/2015)... Dr. Richard Champagne, DMD, MAGD is pleased to ... America’s Best Dentist Award, given by the National Consumer ... dentist is a reflection of his vast experience in ... for his patients. , Each year, the National Consumer ... field. These nominees are dentists who have exceptionally high ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Sylvia Hawthorn-Deppen shared ... hopes that it would remind others in similar situations that ... Recovery from Chronic Pain and Discovery of New Energy” (published ... a new audience via a renewed press campaign. , “I ... debilitating pain ,” Hawthorn-Deppen says. “As an adolescent I ...
Breaking Medicine News(10 mins):Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 3Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2Health News:Author launches new press campaign for 2012 book ‘Wheel’ 2
... Teens Still Feel Targeted By Tobacco Advertising and Find ... Kids across Delaware,will rally against tobacco on April 2 ... 13th annual Kick Butts Day, sponsored by the,Campaign for ... (for a list of local events, go to ...
... By Tobacco Advertising and Find It,Easy to Buy Cigarettes, ... against tobacco on April 2 as they join thousands ... Day, sponsored by the,Campaign for Tobacco-Free Kids. Hundreds of ... local events, go to, http://www.kickbuttsday.org/events )., This year, ...
... (OTC,Bulletin Board: BNLB) is pleased to announce that sales ... at the beginning of this year, have,exceeded the company,s ... 2008., Fusion,s 6+ Hour Energy Shot was first ... past November, where it was voted,"Best Tasting Shot". Fusion ...
... N.C., March 27 Marshall Erdman &,Associates ... company by,"Modern Healthcare,s" 2008 Construction & Design ... the healthcare industry; it,examines year-over-year sales, contracted ... in business and number of architects, engineers,and ...
... 27 Biotest Pharmaceuticals,Corporation, a leading developer ... announcement that a Hepatitis B Immune Globulin,Intravenous ... received,Orphan Drug designation by the U.S. Food ... hepatitis B recurrence following orthotopic liver,transplantation., ...
... major licensing deals like the one his company recently ... front of mind for rising Australian biotechnology star, Antisense ... when he meets with leading industry figures in the ... scientists chosen from a highly competitive field of candidates ...
Cached Medicine News:Health News:Delaware Kids 'Kick Butts' on April 2 2Health News:Delaware Kids 'Kick Butts' on April 2 3Health News:Georgia Kids 'Kick Butts' on April 2 2Health News:Georgia Kids 'Kick Butts' on April 2 3Health News:Bond Laboratories' First Quarter Fiscal 2008 Sales Exceeding Internal Projections 2Health News:'Modern Healthcare' Names Marshall Erdman Nation's Top Design-Build Company 2Health News:Biotest Pharmaceuticals Corporation Responds to Orphan Drug Act Announcement 2Health News:Antisense therapeutics scientist out to pull more big deals 2
Freedom of movement - plus full circle, maximum radiation protection. No other full circle radiation protection design approaches the level of comfort of the VestSkirt, which divides weight between t...
... Cryo System is the first in portability and performance. ... surgeons who need a flexible, portable system with the ... CTU attaches easily to an "E" size tank and ... cryo to where it is needed.,The CTU Travel Case ...
... an easy-to-use, workflow-based system designed to save you ... of the SleepWorks software and either the Connex ... systems can be used for a complete range ... full EEG recording - and have superior signal ...
... Merci Retrieval System is made up of ... Merci Microcatheter and the Merci Balloon Guide ... Once the location of the clot has ... Guide Catheter is inserted through a small ...
Medicine Products: